http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2746642-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2f1bd9861c9adecaaeb6310a1a8f679
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-20
filingDate 2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9b4a5d285bfd084902eba697e946246
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50f983aa95af2cb5e92a0421892be4c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_969c91c641055f29dc047f375dd2e072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a23dfd5e5a3f972fa5aeb3ab7159e03e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc440fb829bda7cf9b2d8b90cfec4af2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f1354ad308de929fb0829971d2e65d9
publicationDate 2021-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2746642-C1
titleOfInvention Method for complex sequential use of pathogenetic agents in treatment in children with tuberculosis infection
abstract FIELD: medicine.SUBSTANCE: present invention relates to medicine, namely to phthisiology, and concerns the complex sequential use of pathogenetic agents for the treatment of children with tuberculosis infection. To do this, a vetoron is driven once daily, 0.5-0.6 ml, diluted in 100 ml of boiled water, after meals, with a course of 1-3 months, repeated after 1 month. Additionally, with the development of intestinal dysbiosis of 2-3 degrees of severity, a daily single intake of kumis is prescribed 2 hours after taking medications, in slow sips, while a single drinking dose of kumis is 100-150 ml, and the course of intake is 3 months.EFFECT: this sequence of administration of vitamin and fermented milk products provides an increase in the effectiveness of treatment of tuberculosis infection by increasing the immune status and eliminating hepatotoxic side reactions that develop during treatment with anti-tuberculosis drugs.1 cl, 2 ex
priorityDate 2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2611391-C1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414865469
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280489
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426078961
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551405
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9502
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5353436
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503663
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14052
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523438
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1046

Total number of triples: 38.